BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36361723)

  • 1. Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer.
    Jang H; Choi CM; Lee SH; Lee S; Jeong MK
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.
    Jamal-Hanjani M; Wilson GA; Horswell S; Mitter R; Sakarya O; Constantin T; Salari R; Kirkizlar E; Sigurjonsson S; Pelham R; Kareht S; Zimmermann B; Swanton C
    Ann Oncol; 2016 May; 27(5):862-7. PubMed ID: 26823523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
    Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
    Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
    [No Abstract]   [Full Text] [Related]  

  • 4. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
    Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
    Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
    Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
    Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible.
    Jensen TJ; Goodman AM; Ellison CK; Holden KA; Kato S; Kim L; Daniels GA; Fitzgerald K; McCarthy E; Nakashe P; Mazloom AR; Almasri E; McLennan G; Grosu DS; Eisenberg M; Kurzrock R
    Mol Cancer Ther; 2021 Nov; 20(11):2274-2279. PubMed ID: 34465593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copy number alterations detected by whole-exome and whole-genome sequencing of esophageal adenocarcinoma.
    Wang X; Li X; Cheng Y; Sun X; Sun X; Self S; Kooperberg C; Dai JY
    Hum Genomics; 2015 Sep; 9(1):22. PubMed ID: 26374103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
    Yu Y; Qian J; Shen L; Ji W; Lu S
    Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.
    Ge G; Peng D; Guan B; Zhou Y; Gong Y; Shi Y; Hao X; Xu Z; Qi J; Lu H; Zhang X; Zhan Y; Li Y; Wu Y; Ding G; Shen Q; He Q; Li X; Zhou L; Ci W
    Clin Chem; 2020 Jan; 66(1):188-198. PubMed ID: 31811000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
    Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
    Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
    Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
    PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 13. Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.
    Dietz S; Schirmer U; Mercé C; von Bubnoff N; Dahl E; Meister M; Muley T; Thomas M; Sültmann H
    PLoS One; 2016; 11(8):e0161012. PubMed ID: 27529345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
    Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
    Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
    Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
    Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
    Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
    Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data.
    Oh S; Geistlinger L; Ramos M; Morgan M; Waldron L; Riester M
    JCO Clin Cancer Inform; 2020 Apr; 4():321-335. PubMed ID: 32282230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach.
    Beagan JJ; Drees EEE; Stathi P; Eijk PP; Meulenbroeks L; Kessler F; Middeldorp JM; Pegtel DM; Zijlstra JM; Sie D; Heideman DAM; Thunnissen E; Smit L; de Jong D; Mouliere F; Ylstra B; Roemer MGM; van Dijk E
    J Mol Diagn; 2021 Nov; 23(11):1553-1563. PubMed ID: 34454114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
    Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
    J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.